Skip to main content

Table 2 Baseline characteristics of patients in each enrolled trial

From: Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review

Source

No.

Age (years)*

Female (%)

BMI (kg/m2)*

Smoking (Pack-year)

Pre-bronchodilator FEV1% predicted*

FeNO (ppb)*

Positive atopic status (%)

Diagnosis or duration of asthma (years)*

Barnes 2012 [11]

65

43.4 (18–55)**

41.53

NM

≤10

NM

NM

100

6.5 (6.29)

Pettipher 2014 [12]

125

40.4 (11.4)

70

NM

< 10

71.5 (6.1)

NM

NM

NM

123

39.7 (10.2)

81

NM

< 10

71.0 (6.2)

NM

NM

NM

117

38.9 (11.4)

76

NM

< 10

71.5 (6.9)

NM

NM

NM

Singh 2013 [13]

21

31.1 (7.1)

14.3

NM

< 10

87.4 (12.0)

32.7 (21.8)

100

NM

Hall (trial 1) 2015 [14]

77

39.1 (11.5)

53.2

27.0 (4.6)

< 10

71.4 (7.3)

NM

75.3

NM

83

35.1 (11.1)

50.6

25.9 (4.3)

< 10

73.3 (7.3)

NM

78.3

NM

79

37.5 (12.2)

54.4

26.5 (4.7)

< 10

73.6 (6.9)

NM

84.8

NM

Hall (trial 2) 2015 [14]

81

41.8 (12.7)

61.7

27.6 (4.1)

< 10

72.6 (7.6)

NM

82.7

NM

Bateman 2017 [16]

201

45.2 (12.1)

59.2

28.1 (5.7)

0

64.4 (9.6)

NM

100

20.5 (14.9)

219

45.6 (12.1)

54.34

26.9 (5.0)

0

64.1 (10.1)

NM

100

20.5 (14.9)

212

43.5 (12.3)

60.85

27.4 (5.5)

0

64.5 (9.7)

NM

100

18.4 (14.0)

133

45.8 (12.5)

54.89

27.8 (5.0)

0

63.7 (10.5)

NM

100

21.2 (15.0)

Busse 2013 [17]

79

44.7 (11.5)

65.8

29.6 (6.2)

< 10

68.2 (7.9)

31.9 (21.4)

93.7

28.0 (14.1)

79

45.0 (11.3)

58.2

32.0 (6.5)

< 10

67.1 (7.9)

30.9 (30.5)

91.1

24.8 (13.2)

79

44.6 (11.4)

69.8

31.9 (8.0)

< 10

66.7 (8.5)

28.3 (23.2)

91.1

28.9 (14.5)

80

43.7 (11.4)

40.0

31.4 (7.2)

< 10

66.1 (8.9)

33.5 (31.6)

95.0

27.3 (12.8)

Erpenbeck 2016 [18]

82

41 (12.9)

24

28.5 (5.81)

< 10

71.5 (7.11)

32 (NM)

100

NM

Fowler 2017 [19]

63

33.1 (10.9)

NM

24.2 (2.9)

< 10

85.2 (15.0)

NM

NM

NM

Gonem 2016 [20]

30

50 (17)

40

31.0 (5.9)

NM

72.5 (23.8)

30 (24)

87

32 (16)

Kuna (trial 1) 2016 [21]

57

38.4 (NM)

16

26.3 (NM)

< 10

82.6 (NM)

NM

100

13 (NM)

Kuna (trial 2)2016 [21]

95

43.3 (NM)

28

26.9 (NM)

< 10

66.2 (NM)

NM

72

11.1 (NM)

90

43.0 (NM)

21

27.0 (NM)

< 10

68.5 (NM)

NM

77

12.1 (NM)

92

43.5 (NM)

37

27.2 (NM)

< 10

69.0 (NM)

NM

64

10 (NM)

Wenzel 2014 [22]

93

35 (18–68)**

49

26.0 (19.3–34.6)**

< 10

73.4 (60–84)***

47.5 (26–244)**

100

NM

Bateman 2018 [23]

976

41.0 (NM)

49.5

27.5 (NM)

≤10

NM

NM

100

18.2 (NM)

Diamant 2014 [24]

18

30.6 (21–46)**

0

25.58 (NM)

< 10

NM

51.6 (38.5)

100

NM

Miller 2017 [25]

108

41.1 (12.4)

53.7

28.8 (4.8)

< 10

72.8 (7.6)

NM

63.9

28.2 (12.9)

  1. Data was expressed as *mean (SD), ** mean (range), *** median (range)
  2. BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in one second, NM not mentioned